Copenhagen

Introducing Cercle - AI Bridging the Gap in Women's Healthcare

Retrieved on: 
Wednesday, November 8, 2023
Fertility, Knowledge, Woman, FDA, RWD, Roger Hawkins (drummer), Copenhagen, HIPAA, Real world evidence, Genetics, Congress, Medtech, USF, RWE, Research, University of Copenhagen Faculty of Health and Medical Sciences, IVF, Genomics, Real, Medicine, Partnership, University, Privacy, Clinic, AI, Real world data, Patient, Acceleration, Medical imaging, Medical device, Nursing, Cercle

SAN FRANCISCO, Nov. 8, 2023 /PRNewswire/ -- Cercle, an AI technology company unlocking comprehensive and secure data insights for the healthcare industry, announced its launch today. Its technology platform, the Cercle™ Biomedical Graph, is the first and only of its kind, harnessing and connecting billions of anonymized biomedical and genomics data points drawn securely from healthcare clinics and research labs around the world. When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem. These data insights can accelerate medical discoveries in the pharmaceutical and research fields, enable the acceleration of precision medicine and personalized treatments, help clinics improve the efficiency and effectiveness of  medical care, and ultimately, drive better health outcomes. The company has already partnered with two trusted healthcare institutions, Eurofins Genoma and US Fertility.

Key Points: 
  • When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem.
  • Cercle is launching first in fertility and women's healthcare, ushering in a new age of accuracy, knowledge and clarity in a historically under-researched and under-funded medical field.
  • Cercle utilizes AI technology to harmonize and transform this raw and fragmented data into accurate insights that help improve patient outcomes.
  • Cercle plans to support doctors, clinics, biotech and pharmaceutical researchers, and healthcare communities across many women's healthcare verticals and needs beyond fertility in the future.

Global Protein Labeling Market Size, Share & Trends Analysis Report 2023-2030 - Innovative Techniques Propel Global Protein Labeling Market Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Biotechnology, Science, Health, Research, Molecular biology, Biomarker, Copenhagen, Cell biology, Reagent, PTM, Investment, Cell, Mass spectrometry, Novo Nordisk Foundation Center for Protein Research, Medical research, University of Copenhagen Faculty of Health and Medical Sciences, Growth, Genomics, Immune system, A-DNA, Neuroscience, Biochemistry, University, USD, Mass, Novo Nordisk Foundation, Proteomics, Biomedicine, Assay, Medical imaging, Vaccine, Pharmaceutical industry

Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.

Key Points: 
  • Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.
  • The application of advanced quantification methods, such as iodoTMTzero Label Reagent, is facilitating the efficient detection of PTMs, propelling the market forward.
  • Biomedical research is at the forefront of driving growth in the global protein labeling market.
  • The surge in PTM studies, fueled by breakthroughs in protein expression quantification and innovative tagging strategies, is a pivotal factor.

Globally Known Professor and Dermatologist Joins LEO Pharma

Retrieved on: 
Monday, October 9, 2023
Biotechnology, Other Health, Health, Science, Research, Congress, Professor, Journal of the European Academy of Dermatology and Venereology, Egeberg, Human, University of Copenhagen Faculty of Health and Medical Sciences, Epidemiology, International Operational Service Medal, University, Bispebjerg Hospital, LEO, Patient, Head, Copenhagen, Pfizer, Leo Pharma, Skin, Pharmaceutical industry, Dermatology, Venereology

LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs.
  • Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology.
  • He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background.
  • “I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs.

Evecxia Therapeutics Announces CEO Transition

Retrieved on: 
Thursday, September 14, 2023
Other Consumer, Research, Mental Health, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Other Science, Duke University, NeuroSearch, Lundbeck, University, DSM-IV codes, Patient, Drug discovery, IT University of Copenhagen, Therapy, Safety, Copenhagen, Pharmaceutical industry, Neuropharmacology

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.

Key Points: 
  • Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.
  • Dr. Jacobsen succeeds Joseph Patti, Ph.D., who has stepped down from his role as President and CEO of Evecxia to pursue other interests.
  • While a scientist at Duke University, he co-founded Evecxia with the late James B Duke Professor, Dr. Marc Caron.
  • “I am excited to be leading Evecxia at this pivotal time in the Company’s history,” said Dr. Jacobsen.

Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.

Retrieved on: 
Wednesday, August 30, 2023
Laboratory, Obesity, University, Novo Nordisk, Research, Embark, Acquisition, Copenhagen, Obesity (journal), Novo Nordisk Foundation, University of Copenhagen Faculty of Health and Medical Sciences, Biology, Conditional sentence, Pharmaceutical industry

The research and development collaboration with Embark Laboratories provide Novo Nordisk with the option to acquire selected assets based on the Embark Biotech discoveries across several indications, including obesity and type 2 diabetes.

Key Points: 
  • The research and development collaboration with Embark Laboratories provide Novo Nordisk with the option to acquire selected assets based on the Embark Biotech discoveries across several indications, including obesity and type 2 diabetes.
  • Brian Finan, Vice President of Obesity Research at Novo Nordisk, said: "Novo Nordisk has been engaged in obesity research for 25 years, and we continuously search for new ways to address this serious chronic disease.
  • We are excited about the opportunity to advance Embark Biotech's lead program and look forward to co-creating novel treatments for cardiometabolic diseases with Embark Laboratories to complement our in-house R&D,".
  • We are thrilled to pass on the baton for our lead metabolic program to Novo Nordisk.

Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.

Retrieved on: 
Wednesday, August 30, 2023
Laboratory, Obesity, University, Novo Nordisk, Research, Embark, Acquisition, Copenhagen, Obesity (journal), Novo Nordisk Foundation, University of Copenhagen Faculty of Health and Medical Sciences, Biology, Conditional sentence, Pharmaceutical industry

The research and development collaboration with Embark Laboratories provide Novo Nordisk with the option to acquire selected assets based on the Embark Biotech discoveries across several indications, including obesity and type 2 diabetes.

Key Points: 
  • The research and development collaboration with Embark Laboratories provide Novo Nordisk with the option to acquire selected assets based on the Embark Biotech discoveries across several indications, including obesity and type 2 diabetes.
  • Brian Finan, Vice President of Obesity Research at Novo Nordisk, said: "Novo Nordisk has been engaged in obesity research for 25 years, and we continuously search for new ways to address this serious chronic disease.
  • We are excited about the opportunity to advance Embark Biotech's lead program and look forward to co-creating novel treatments for cardiometabolic diseases with Embark Laboratories to complement our in-house R&D,".
  • We are thrilled to pass on the baton for our lead metabolic program to Novo Nordisk.

Henkel Appoints North America President

Retrieved on: 
Wednesday, August 16, 2023
Adhesive, Heart, Novozymes, Henkel North American Consumer Goods, University, Detergent, Bond markets in East Asia and South East Asia, Final good, Corporation, IT University of Copenhagen, Growth, United States Naval Forces Europe-Africa, Metal, Copenhagen, Management

STAMFORD, Conn., Aug. 16, 2023 /PRNewswire/ -- Henkel, a leading manufacturer of well-known consumer brands including Persil®, Purex®, and all® laundry detergents, and global leader in the industrial business for adhesives, sealants and functional coatings, announced that it has named Pernille Lind Olsen as President of the North America region.

Key Points: 
  • She also serves as Corporate Senior Vice President Adhesive Technologies Packaging & Consumer Goods; and Regional Head Adhesive Technologies, North America.
  • In her role as President Henkel North America, Lind Olsen succeeds Steven Essick who has retired after 27 years with the company.
  • Lind Olsen is well-positioned to lead Henkel North America with an entrepreneurial and strategic mindset, shaped by her significant global market knowledge and business development experiences.
  • Her background in leading diverse and high-performing teams will empower the Henkel North America teams to bring value to our customers and drive growth across industries and markets.

VTEX Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Software, Marketing, Data Management, Communications, Technology, Apps, Applications, Online Retail, Retail, Partnership, Quarter, International Accounting Standards Committee, Easter, MINI, Omnichannel, Bank statement, Risk, USD, Midea, DIY, BMW Motorrad, BMW, FX, Commerce, Indian stock exchange, MetaCreations, Architecture, Yoy, Growth, GMV, NYSE, Copenhagen, Automation, Cryptocurrency, Tourism, Video game, Drug, Online shopping, Bank

VTEX (NYSE: VTEX) the global enterprise digital commerce platform for premier brands and retailers, today announced results for the second quarter of 2023 ended June 30, 2023.

Key Points: 
  • VTEX (NYSE: VTEX) the global enterprise digital commerce platform for premier brands and retailers, today announced results for the second quarter of 2023 ended June 30, 2023.
  • Non-GAAP subscription gross profit was US$33.7 million in the second quarter of 2023, compared to US$26.6 million in the second quarter of 2022, representing a YoY increase of 26.9% in USD and 25.8% on an FX neutral basis.
  • Non-GAAP subscription gross margin was 75.3% in the second quarter of 2023, compared to 72.5% in the same quarter of 2022.
  • Non-GAAP loss from operations was US$1.5 million during the second quarter of 2023, compared to a Non-GAAP loss from operations of US$4.1 million in the first quarter of 2023 and a Non-GAAP loss from operations of US$17.5 million in the same quarter of 2022.

Shenzhen to Foster Quantitative Biology Stronghold

Retrieved on: 
Thursday, August 3, 2023
Higher Education Press, SIAT, Baptist University, University, Tsinghua-Berkeley Shenzhen Institute, Education, Institute of Botany, Chinese Academy of Sciences, Systems biology, Niels Bohr Institute, Agriculture, Hope, Los Alamos National Laboratory, Medicine, Research, Science, Advanced technology, Synthetic biology, International Conference on Parallel and Distributed Systems, WEI, Peking University, Copenhagen, Tsinghua University, University of Copenhagen Faculty of Science, Physics, Biology, Guangdong–Hong Kong–Macao Greater Bay Area, Health, Environment, Synthetic, Conference, Shenzhen Institute of Advanced Technology station, LIU, Microscope, Dentistry, Pharmaceutical industry

SHENZHEN, China, Aug. 3, 2023 /PRNewswire/ -- An international conference on quantitative biology was held recently in Southern China's Shenzhen, drawing over 300 participants from more than 20 universities worldwide to discuss illuminating opportunities and shaping the future of quantitative and synthetic biology.

Key Points: 
  • SHENZHEN, China, Aug. 3, 2023 /PRNewswire/ -- An international conference on quantitative biology was held recently in Southern China's Shenzhen, drawing over 300 participants from more than 20 universities worldwide to discuss illuminating opportunities and shaping the future of quantitative and synthetic biology.
  • Jointly organized by the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences, Tsinghua University, Peking University, and the Shenzhen Institute of Synthetic Biology, the 17th Q-Bio on Quantitative Biology provided a dynamic global platform for fostering exchanges in the realm of quantitative biology and its related fields, said Dr. LIU Chenli from SIAT, one of the main organizers of the conference.
  • Quantitative biology, as a typical cutting-edge interdisciplinary field, reveals the design principles and operational laws of biological systems through the organic combination of advanced measurement means and theoretical modeling.
  • The Q-Bio aims to build Shenzhen an "international exchange platform + multidimensional resource collaboration + scientific achievements sharing + accelerated industrial transformation" on synthetic biology.

CLEAR and Denver International Airport Extend DEN Reserve to Help Passengers Save Time at Airport Security

Retrieved on: 
Tuesday, July 11, 2023
Congestion, Travel, EVP, Ball Arena, The Great Hall, CLEAR, Level 6, Home, Bridge, Copenhagen, Sport, DEN, Great hall, NYSE, Denver International Airport, Coors Field, Airline

DENVER, July 11, 2023 /PRNewswire/ -- Amid the busy summer travel season of 2023, Denver International Airport (DEN) has partnered with CLEAR (NYSE: YOU), the secure identity company, and Copenhagen Optimization to extend the popular DEN Reserve powered by CLEAR program to continue helping passengers save time at airport security.

Key Points: 
  • DENVER, July 11, 2023 /PRNewswire/ -- Amid the busy summer travel season of 2023, Denver International Airport (DEN) has partnered with CLEAR (NYSE: YOU), the secure identity company, and Copenhagen Optimization to extend the popular DEN Reserve powered by CLEAR program to continue helping passengers save time at airport security.
  • This option has provided relief at the Bridge Security Checkpoint and created a better experience for passengers.
  • DEN Reserve is separate from CLEAR's opt-in airport membership , which is available to DEN passengers traveling from the North and South security checkpoints.
  • Passengers can reserve a time in any of the RESERVE powered by CLEAR lanes across the U.S. using the Home-to-Gate feature in the free CLEAR app .